Building the bridge between biotech innovation and rare disease access.
Rare disease development requires more than one company, one physician or one market. It requires a coordinated ecosystem of biotech innovators, clinical experts, academic centers, research institutions, patient-access stakeholders, regulatory specialists, data partners and healthcare leaders working toward a common goal: helping promising therapies reach the patients who need them. Pharma²⁸ partners with organizations and individuals across this ecosystem to support the responsible international development of therapies for rare and ultra-rare diseases.
Biotech Companies
Pharma²⁸ works with biotech companies developing therapies for rare and ultra-rare diseases that may benefit from international clinical, regulatory, data or patient-access opportunities.
We help companies evaluate whether Brazil or other international markets may offer relevant patient populations, clinical expertise, evidence-generation opportunities or long-term access potential.
Specialist physicians are central to rare disease development.
Pharma²⁸ works with experienced clinicians, physician-scientists, investigators and centers of excellence to support disease-area insight, patient identification, clinical feasibility, evidence generation and responsible engagement with innovative therapies.
Academic centers and research institutions play a critical role in rare disease innovation.
Pharma²⁸ connects biotech companies with clinical and academic ecosystems that can support scientific collaboration, translational insight, real-world evidence, cohort mapping and clinical development opportunities.
High-volume clinical centers often hold deep expertise, patient cohorts and real-world experience in complex and underdiagnosed conditions.
Pharma²⁸ helps identify and engage institutions with relevant clinical credibility, disease-area focus and the ability to support structured rare disease programs.
For investors and strategic partners, international development can create value beyond traditional market expansion.
Pharma²⁸ helps evaluate how Brazil and other international markets may support clinical validation, patient identification, data generation, market access and long-term strategic value for selected rare disease programs.
Responsible rare disease development requires alignment with local healthcare realities.
Pharma²⁸ engages stakeholders involved in patient access, clinical pathways, healthcare delivery, policy, advocacy and institutional decision-making to help build pathways that are clinically credible, locally informed and oriented toward patient need.
International rare disease programs require strong execution.
Pharma²⁸ works with specialized partners in regulatory strategy, clinical operations, data infrastructure, evidence generation, market access and local implementation to support each program with the expertise required for responsible development.
Pharma²⁸ operates as a strategic bridge.
We connect biotech innovation with the physicians, institutions, patient populations, regulatory pathways, data assets and local expertise needed to evaluate and activate rare disease opportunities in Brazil and other international markets.
Our partnership model is designed to align:
Scientific innovation
Programs anchored in real science.
Unmet medical need
Patients at the center of every decision.
Clinical credibility
Trust with specialists and institutions.
Patient identification
Structured pathways to the right cohorts.
Evidence generation
Real-world and academic evidence.
Regulatory and access pathways
Aligned with local context.
Local institutional trust
Built with credibility and time.
Long-term strategic value
Each partnership strengthens the next.
Each partnership strengthens the pathway for the next one.
Pharma²⁸ combines rare disease intelligence, clinical access, market-entry strategy, data infrastructure and international execution.
Based in Kendall Square, Cambridge, at the center of the Boston biotech ecosystem, and connected to Brazil's clinical and academic landscape, Pharma²⁸ helps partners move from fragmented opportunity to structured action.
We help make international rare disease opportunities more visible, credible and actionable.
We are especially interested in partnerships focused on:
Rare and ultra-rare diseases
Programs anchored in high unmet medical need.
High unmet medical need
Where innovation can meaningfully change outcomes.
Innovative therapies with international potential
Cross-border pathways aligned with real need.
Patient identification challenges
Where finding patients is the hardest problem.
Clinical validation opportunities
Structured evidence generation.
Real-world evidence generation
Longitudinal insight for access and reimbursement.
Academic or institutional collaboration
Trusted, credible partnerships.
Brazil and international market activation
From assessment to execution.
Responsible patient access
Ethical, sustainable pathways to patients.
Our goal is to work with partners who share a commitment to scientific rigor, clinical credibility, ethical access and meaningful patient impact.
If you are a biotech company, physician, researcher, investor, institution or strategic healthcare partner working in rare or ultra-rare diseases, Pharma²⁸ would welcome the opportunity to connect.
Together, we can help transform fragmented clinical, regulatory, data and access opportunities into structured pathways for rare disease innovation.
Let's connect.
If you are exploring international opportunities for a rare disease therapy, clinical program, data initiative or strategic partnership, we would welcome the opportunity to connect.